Radioimmunotherapy of human colon cancer xenografts with 131I-labeled anti-CEA monoclonal antibody

Abstract

Radioimmunotherapy (RIT) is a promising approach for the treatment of a wide variety of malignancies. The aim of this study was to investigate the therapeutic efficacy of (131)I-labeled anticarcinoembryonic antigen (CEA) monoclonal antibody CL58 in a human colon cancer mouse model. In vitro and in vivo characteristics of (125)I-CL58 were evaluated in LS180 human colon cancer cells and the nude mouse model. (131)I-CL58 was prepared and its in vivo therapeutic efficacy was tested. (125)I-CL58 showed high affinity to LS180 cells, as well as high tumor uptake and long tumor retention in LS180 tumor xenografts. (131)I-CL58 exhibited dose-dependent inhibition of LS180 tumor growth. With the excellent in vitro and in vivo characteristics, and the effective therapy for colon cancer in animal model, (131)I-CL58 is a promising agent for RIT of CEA-positive tumors including colon cancer.